CN111818930A - 用于治疗白血病的联合疗法 - Google Patents

用于治疗白血病的联合疗法 Download PDF

Info

Publication number
CN111818930A
CN111818930A CN201980017188.1A CN201980017188A CN111818930A CN 111818930 A CN111818930 A CN 111818930A CN 201980017188 A CN201980017188 A CN 201980017188A CN 111818930 A CN111818930 A CN 111818930A
Authority
CN
China
Prior art keywords
iron
leukemia
artemisinin
arsenic trioxide
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980017188.1A
Other languages
English (en)
Chinese (zh)
Inventor
维克拉姆·马修斯
桑吉夫·克里希纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City St Georges University of London
Original Assignee
St Georges Hospital Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Georges Hospital Medical School filed Critical St Georges Hospital Medical School
Publication of CN111818930A publication Critical patent/CN111818930A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980017188.1A 2018-01-17 2019-01-17 用于治疗白血病的联合疗法 Pending CN111818930A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1800736.9A GB201800736D0 (en) 2018-01-17 2018-01-17 Combination therapy for treatment of leukemia
GB1800736.9 2018-01-17
PCT/GB2019/050124 WO2019141988A1 (en) 2018-01-17 2019-01-17 Combination therapy for treatment of leukemia

Publications (1)

Publication Number Publication Date
CN111818930A true CN111818930A (zh) 2020-10-23

Family

ID=61256143

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980017188.1A Pending CN111818930A (zh) 2018-01-17 2019-01-17 用于治疗白血病的联合疗法

Country Status (6)

Country Link
US (1) US11400112B2 (https=)
EP (1) EP3740215A1 (https=)
JP (1) JP2021510715A (https=)
CN (1) CN111818930A (https=)
GB (1) GB201800736D0 (https=)
WO (1) WO2019141988A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220226372A1 (en) * 2019-05-21 2022-07-21 Medsenic Use of metal ions to potentiate the therapeutic effects of arsenic
EP3868372A1 (en) * 2020-02-19 2021-08-25 JLP Health GmbH A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
CN116687965A (zh) * 2023-05-05 2023-09-05 杭州市西溪医院 一种三氧化二砷-青蒿琥酯抗肿瘤组合物、双载药纳米脂质体及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720011B1 (en) * 1995-08-23 2004-04-13 Ting-Dong Zhang Injectable composition for cancer treatment
CN103202837A (zh) * 2012-01-16 2013-07-17 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于治疗制备白血病的药物
CN103202835A (zh) * 2012-01-16 2013-07-17 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性白血病的药物
CN103202836A (zh) * 2012-01-16 2013-07-17 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性髓细胞性白血病的药物
US20130317095A1 (en) * 2011-01-31 2013-11-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Use of Artemisine Derivatives and Pharmaceutical Salts Thereof
WO2014082569A1 (zh) * 2012-11-29 2014-06-05 昆明制药集团股份有限公司 蒿甲醚在制备治疗白血病的药物中的用途
CN104739824A (zh) * 2013-12-30 2015-07-01 昆山达人生物医药有限公司 双氢青蒿素在制备抑制肿瘤生长药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04273819A (ja) * 1991-02-28 1992-09-30 Takeda Chem Ind Ltd 血圧上昇剤
TR200002243T2 (tr) * 1997-11-10 2000-12-21 Memorial Sloan-Kettering Cancer Center Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
CA2488347A1 (en) * 2002-06-06 2003-12-18 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
JP2008201765A (ja) * 2007-01-26 2008-09-04 Jichi Medical Univ 腫瘍治療における三酸化二ヒ素の副作用低減剤及び解毒剤
US9801851B2 (en) 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
CN103845360A (zh) * 2012-11-29 2014-06-11 昆明制药集团股份有限公司 含蒿甲醚的药物组合物、制剂及其用途
EP3233918A1 (en) * 2014-12-19 2017-10-25 Novartis AG Combination therapies
US9918972B2 (en) 2014-12-23 2018-03-20 The University Of Maryland, Baltimore Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
US10925963B2 (en) 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720011B1 (en) * 1995-08-23 2004-04-13 Ting-Dong Zhang Injectable composition for cancer treatment
US20130317095A1 (en) * 2011-01-31 2013-11-28 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Use of Artemisine Derivatives and Pharmaceutical Salts Thereof
CN103202837A (zh) * 2012-01-16 2013-07-17 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于治疗制备白血病的药物
CN103202835A (zh) * 2012-01-16 2013-07-17 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性白血病的药物
CN103202836A (zh) * 2012-01-16 2013-07-17 上海交通大学医学院附属瑞金医院 青蒿素衍生物及其药用盐用于制备治疗急性髓细胞性白血病的药物
WO2014082569A1 (zh) * 2012-11-29 2014-06-05 昆明制药集团股份有限公司 蒿甲醚在制备治疗白血病的药物中的用途
CN104739824A (zh) * 2013-12-30 2015-07-01 昆山达人生物医药有限公司 双氢青蒿素在制备抑制肿瘤生长药物中的应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HENRY LAI ET AL: "Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin", 《CANCER LETTERS》 *
YING LI ET AL: "Artesunate possesses anti-leukemia properties that can be enhanced by arsenic trioxide", 《LEUKEMIA & LYMPHOMA》 *
彭宇: "青蒿素衍生物SM1044抗急性髓性白血病的作用和机制研究", 《万方数据知识服务平台》 *
曹履先等主编: "《曹履先教授从医60年学术论文集》", 30 June 2012, 军事医药科学出版社 *
梅全喜主编: "《现代中药药理与临床应用手册》", 31 October 2008, 中国中医药出版社 *
编辑委员会编: "《中国肿瘤临床年鉴》", 30 September 2016, 中国协和医科大学出版社 *

Also Published As

Publication number Publication date
JP2021510715A (ja) 2021-04-30
GB201800736D0 (en) 2018-02-28
US20200345770A1 (en) 2020-11-05
WO2019141988A1 (en) 2019-07-25
EP3740215A1 (en) 2020-11-25
US11400112B2 (en) 2022-08-02

Similar Documents

Publication Publication Date Title
KR20180006389A (ko) 화학요법 및 방사선요법 유도 인지 장애, 신경병증 및 비활동성을 치료하기 위한 nad+ 표적화
CN111818930A (zh) 用于治疗白血病的联合疗法
KR20180116298A (ko) 화학요법 유도 심장독성에 대응하기 위한 약제학적 조성물 및 방법
WO2017091644A1 (en) Compositions and methods for treating ischemic stroke
ES2673158T3 (es) Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA
EP1093369A2 (de) Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum
RU2492862C2 (ru) Противоопухолевые средства с бензофенантридиновой структурой и содержащие их препараты
JP2018533560A (ja) 癌を治療するための併用療法
US20160000793A1 (en) Sodium channel blocker for treatment of loss of superficial sensitivity
AU2019200353A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
JP2012532855A (ja) 医薬として使用するための組合せ製剤
KR20260023551A (ko) 정맥내 제형에서의 니코틴아미드 리보시드 및 이의 유도체 및 이의 사용 방법
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
US20010034358A1 (en) Viral treatment
JP5830983B2 (ja) 抗癌剤の副作用軽減剤
Parab Hydroxyurea: Occurrence, uses and side effects
US20250339429A1 (en) Methods of treating ulk3-associated cancers
CN113939342A (zh) 连接三苯基膦鎓的水杨胺衍生物
US20240082181A1 (en) Method for Treating Blood Cancers
AU2005210221A1 (en) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
KR20200021895A (ko) 테라노스틱 항암제 전구체, 이의 제조방법 및 이의 용도
US20050187288A1 (en) Beta-lapachone and methods of treating cancer
JP2019131508A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
WO2023174314A1 (zh) 氮杂环丁烷衍生物的用途及治疗方法
CA3227596A1 (en) Methods for treating nervous system disorders with antipurinergic agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Vicram Matthews

Inventor after: Sangiev Krishna

Inventor after: Yolanda Sidney Augustine

Inventor before: Vicram Matthews

Inventor before: Sangiev Krishna

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201023